目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. EXPECTORANT DRUG MARKET, BY DRUG TYPE (USD BILLION)
6.1. Guaifenesin
6.2. Bromhexine
6.3. Ambroxol
6.4. Potassium Iodide

7. EXPECTORANT DRUG MARKET, BY FORMULATION (USD BILLION)
7.1. Tablets
7.2. Syrups
7.3. Oral Solutions
7.4. Granules

8. EXPECTORANT DRUG MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)
8.1. Oral
8.2. Injectable
8.3. Inhalation

9. EXPECTORANT DRUG MARKET, BY INDICATION (USD BILLION)
9.1. Chronic Obstructive Pulmonary Disease
9.2. Asthma
9.3. Bronchitis

10. EXPECTORANT DRUG MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA

11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Expectorant Drug Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Expectorant Drug Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023

12. COMPANY PROFILES
12.1. Pfizer
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Roche
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Mylan
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. BristolMyers Squibb
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Johnson and Johnson
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. GlaxoSmithKline
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. AstraZeneca
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. AbbVie
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Takeda Pharmaceutical
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Merck and Co
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Novartis
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Teva Pharmaceutical Industries
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Boehringer Ingelheim
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Sanofi
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies

13. APPENDIX
13.1. References
13.2. Related Reports

LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 8. US EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 9. US EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 10. US EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 11. US EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 28. UK EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 29. UK EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 30. UK EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 31. UK EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 58. APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 59. APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 60. APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 61. APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 128. MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 129. MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 130. MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 131. MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA EXPECTORANT DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS
FIGURE 3. US EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 4. US EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 5. US EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 6. US EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 7. US EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 9. CANADA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 10. CANADA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 11. CANADA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 12. CANADA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE EXPECTORANT DRUG MARKET ANALYSIS
FIGURE 14. GERMANY EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 15. GERMANY EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 16. GERMANY EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 17. GERMANY EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 18. GERMANY EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 20. UK EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 21. UK EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 22. UK EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 23. UK EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 25. FRANCE EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 26. FRANCE EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 27. FRANCE EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 28. FRANCE EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 30. RUSSIA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 31. RUSSIA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 32. RUSSIA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 33. RUSSIA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 35. ITALY EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 36. ITALY EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 37. ITALY EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 38. ITALY EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 40. SPAIN EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 41. SPAIN EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 42. SPAIN EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 43. SPAIN EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 45. REST OF EUROPE EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 46. REST OF EUROPE EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 47. REST OF EUROPE EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 48. REST OF EUROPE EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC EXPECTORANT DRUG MARKET ANALYSIS
FIGURE 50. CHINA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 51. CHINA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 52. CHINA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 53. CHINA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 54. CHINA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 56. INDIA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 57. INDIA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 58. INDIA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 59. INDIA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 61. JAPAN EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 62. JAPAN EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 63. JAPAN EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 64. JAPAN EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 66. SOUTH KOREA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 67. SOUTH KOREA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 68. SOUTH KOREA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 69. SOUTH KOREA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 71. MALAYSIA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 72. MALAYSIA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 73. MALAYSIA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 74. MALAYSIA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 76. THAILAND EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 77. THAILAND EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 78. THAILAND EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 79. THAILAND EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 81. INDONESIA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 82. INDONESIA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 83. INDONESIA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 84. INDONESIA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 86. REST OF APAC EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 87. REST OF APAC EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 88. REST OF APAC EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 89. REST OF APAC EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS
FIGURE 91. BRAZIL EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 92. BRAZIL EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 93. BRAZIL EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 94. BRAZIL EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 95. BRAZIL EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 97. MEXICO EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 98. MEXICO EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 99. MEXICO EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 100. MEXICO EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 102. ARGENTINA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 103. ARGENTINA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 104. ARGENTINA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 105. ARGENTINA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 107. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 108. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 109. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 110. REST OF SOUTH AMERICA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA EXPECTORANT DRUG MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 113. GCC COUNTRIES EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 114. GCC COUNTRIES EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 115. GCC COUNTRIES EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 116. GCC COUNTRIES EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 118. SOUTH AFRICA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 119. SOUTH AFRICA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 120. SOUTH AFRICA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 121. SOUTH AFRICA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA EXPECTORANT DRUG MARKET ANALYSIS BY DRUG TYPE
FIGURE 123. REST OF MEA EXPECTORANT DRUG MARKET ANALYSIS BY FORMULATION
FIGURE 124. REST OF MEA EXPECTORANT DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 125. REST OF MEA EXPECTORANT DRUG MARKET ANALYSIS BY INDICATION
FIGURE 126. REST OF MEA EXPECTORANT DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF EXPECTORANT DRUG MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF EXPECTORANT DRUG MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: EXPECTORANT DRUG MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: EXPECTORANT DRUG MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: EXPECTORANT DRUG MARKET
FIGURE 133. EXPECTORANT DRUG MARKET, BY DRUG TYPE, 2024 (% SHARE)
FIGURE 134. EXPECTORANT DRUG MARKET, BY DRUG TYPE, 2019 TO 2032 (USD Billions)
FIGURE 135. EXPECTORANT DRUG MARKET, BY FORMULATION, 2024 (% SHARE)
FIGURE 136. EXPECTORANT DRUG MARKET, BY FORMULATION, 2019 TO 2032 (USD Billions)
FIGURE 137. EXPECTORANT DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
FIGURE 138. EXPECTORANT DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2032 (USD Billions)
FIGURE 139. EXPECTORANT DRUG MARKET, BY INDICATION, 2024 (% SHARE)
FIGURE 140. EXPECTORANT DRUG MARKET, BY INDICATION, 2019 TO 2032 (USD Billions)
FIGURE 141. EXPECTORANT DRUG MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. EXPECTORANT DRUG MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS